Clinical Trials in Latvia

• A Phase 2 Study of AMG 193 in Subjects With MTAP-deleted Advanced NSCLC Recruiting
  2024-514459-14-00 Phase II Non-Small Cell Lung Cancer Amgen Inc.
• A dose ranging study to investigate efficacy and safety of subcutaneous TOUR006 compared with placebo in participants 18 to 80 years of age … Recruiting
  2024-514801-69-00 Phase II Thyroid Eye Disease Tourmaline Bio Inc.
• A prospective randomized open-label phase II clinical study evaluating the efficacy and safety of zoledronic acid addition to standard thera… Recruiting
  2024-519446-67-00 Phase II Glioblastoma Pauls Stradins Clinical University Hospital
• A study to assess the Efficacy and Safety of Efgartigimod IV in Adult Participants with Primary Immune Thrombocytopenia Recruiting
  2024-515451-38-00 Phase III Primary Immune thrombocytopenia (ITP) Argenx
• An Adaptive, Dose-Ranging, Phase 2 Study of Eltrekibart Given Alone or in Combination with Mirikizumab for the Treatment of Adult Patients w… Recruiting
  2023-507853-13-00 Phase II Ulcerative Colitis Eli Lilly & Co.
• Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN). Recruiting
  2024-514135-17-00 Phase III Immunoglobulin A Nephropathy Alpine Immune Sciences Inc.
• Study BT8009-230 in Subjects with Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) Recruiting
  2023-504231-41-01 Phase II/III Locally advanced or metastatic urothelial cancer Bicycletx Limited
• A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participant… Recruiting
  2023-505678-14-00 Phase II Ulcerative Colitis AbbVie Deutschland GmbH & Co. KG
• CHIP-AML22/Quizartinib sub-study: study of the safety and efficacy of quizartinib in children and adolescents with FLT3-ITD positive AML wit… Recruiting
  2023-505000-27-01 Phase II newly diagnosed pediatric FLT3-ITD positive and NPM1 wild-ty… Prinses Maxima Centrum voor Kinderoncologie B.V.
• Clairleaf TM: A study to test long-term treatment with BI 1291583 in people with bronchiectasis who took part in a previous study with this … Recruiting
  2023-503290-38-00 Phase II Bronchiectasis Boehringer Ingelheim Espana S.A.; Boehringer Ingelheim International GmbH; Boehr…
• Open-label, long-term safety, efficacy, and pharmacokinetics study of vibegron in pediatric subjects 2 years to < 18 years of age with NDO a… Recruiting
  2024-513995-16-00 Phase II/III Neurogenic Detrusor Overactivity (NDO) Sumitomo Pharma America Inc.
• Combined Dose-Finding and CV Outcomes Study with CSL300 (Clazakizumab) in Adult Subjects with ESKD Undergoing Dialysis (POSIBIL6ESKD). Recruiting
  2022-500273-14-00 Phase II/III Atherosclerotic cardiovascular disease in patients with ESKD CSL Behring LLC
• A Phase 3, Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Contezolid Acefosamil and Contezolid Compared … Recruiting
  2022-500257-16-00 Phase III Diabetic Foot Infections Micurx Pharmaceuticals Inc.
• Efficacy and safety of ofatumumab and siponimod compared to fingolimod in pediatric patients with multiple sclerosis Recruiting
  2024-511686-11-00 Phase III Multiple Sclerosis in pediatric patients Novartis Pharma AG
• A clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosi… Recruiting
  2025-521546-23-00 Phase III Secondary progressive multiple sclerosis Novartis Pharma AG
• Therapeutic equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a in subjects with mild to moderate asthma (TRECONY) Recruiting
  2025-521456-35-00 Phase II Mild to moderate asthma Chiesi Farmaceutici S.p.A.
• Clinical Study to Compare Efficacy and Safety of AVT29 and Eylea HD in Participants with Diabetic Macular Edema Recruiting
  2025-522231-34-00 Phase III Diabetic Macular Edema Alvotech Swiss AG
• A clinical study of opevesostat and standard hormone therapy in people with prostate cancer (MK-5684-004) Recruiting
  2023-504957-11-00 Phase III Metastatic castration resistant prostate cancer Merck Sharp & Dohme LLC
• ROC-101 Safety and Tolerability Study in Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung … Recruiting
  2025-522074-37-00 Phase II Pulmonary Arterial Hypertension (PAH), Pulmonary Hypertensio… Allrock Bio Inc.
• A Phase 3, Randomized, Double-Masked, Active-Controlled Trial of a Single Intravitreal Injection of 4D-150 in Adults with Macular Neovascula… Recruiting
  2025-521349-25-00 Phase III Macular neovascularization secondary to age-related macular … 4d Molecular Therapeutics Inc.
• Study to Evaluate Plozasiran in Adults with Hypertriglyceridemia (SHASTA-10 Study) Recruiting
  2024-519712-13-00 Phase III Hypertriglyceridemia (HTG) Arrowhead Pharmaceuticals Inc.
• A Phase 2b Study to Assess the Efficacy and Safety of IMVT-1402 in Patients With Graves' Disease Recruiting
  2025-521920-31-00 Phase II Graves’ Disease Immunovant Sciences GmbH
• REGN7508 versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults. Recruiting
  2025-520478-20-00 Phase III Thromboembolic disease Regeneron Pharmaceuticals Inc.
• EASi-PROTKT™ - A study to test vicadrostat (BI 690517) taken together with empagliflozin in people with type 2 diabetes, high blood pressure… Recruiting
  2025-521188-11-00 Phase III Type 2 diabetes Boehringer Ingelheim Espana S.A.; Boehringer Ingelheim International GmbH

Showing 25–48 of 198 trials